5 Biotech Stocks with Biggest Upside

4. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Average Target Price: $82.70

Potential Upside: 117.8%

Number of Hedge Fund Holders: 29

Value of Hedge Fund Holdings: $758,970,450

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Cambridge, Massachusetts-based biotech company that was founded in 2014 by Nessan Bermingham. The clinical-stage genome editing company is focused on developing curative therapeutics using CRISPR technology.

Intellia Therapeutics, Inc.’s (NASDAQ:NTLA) most advanced program is NTLA-2001 for treating transthyretin (ATTR) amyloidosis. It is the first-ever systemically administered CRISPR therapy candidate to enter clinical trials. Other pipeline programs include editing candidates for hemoglobinopathies like sickle cell disease and beta-thalassemia, autoimmune diseases, and cancer immunotherapies. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has a broad intellectual property portfolio and proprietary editing platform built around CRISPR/Cas9 technology.